Abstract 812P
Background
Gynecological cancer in women may have negative mental and societal consequences impacting not only patients, but also their family members. The impact may differ between families afflicted by cervical and endometrial cancer, as the two cancers develop at different ages (median age at diagnosis 49 vs. 60 years, respectively), and is not well understood. We assessed the health and education status of family members to a woman with cervical or endometrial cancer, to elucidate potential mental and socioeconomic consequences in these.
Methods
We performed a population-based nested case-control study in Sweden, identifying 11,602 cases of cervical cancer and 34,007 cases of endometrial cancer diagnosed during 1991-2016. Each cancer case was matched with five healthy controls randomly selected from the population with same birth year. Their children and respective co-parents were identified through the Swedish multi-generation register and mental health and educational outcomes traced through the Swedish Patient Register and Statistics Sweden. A comprehensive set of mental disorders of co-parents and children and attained highest level of education of the children after mother’s diagnosis, were assessed.
Results
Co-parents and children of cervical cancer patients had 30-40% increased risk of mental disorders after women’s cancer diagnosis compared to relatives of healthy controls. The increase among children emerged right after cancer diagnosis (OR=1.32, 95%CI=1.05-1.65), whereas among the co-parents emerged from 2 years after (OR=1.42, 95%CI=1.02-1.98). For endometrial cancer, the association was present but weaker. Children aged 0-18 at mothers’ cervical cancer diagnosis were less likely to reach a higher level of education as compared to children to women without cervical cancer (OR 0.87, 95%CI 0.83-0.91). The corresponding educational impact on children of women with endometrial cancer was inconclusive.
Conclusions
Children and co-parents of women with cervical or endometrial cancer are affected adversely mentally after the cancer diagnosis, and children to mothers with cervical cancer display a generational impact in terms of lower education attainment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Karolinska Institutet.
Funding
MSD Sweden.
Disclosure
K. Sundström: Financial Interests, Institutional, Research Funding: Merck. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. J. Wang: Financial Interests, Institutional, Funding: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11